Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Isradipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 3/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.45 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.45 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isradipine SCHEMBL1172992 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP1A2CYP3A4CYP2C19ADORA3 | |
| Isradipine SCHEMBL34555 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP1A2CYP3A4CYP2C19ADORA3 | |
| (S)-Isradipine SCHEMBL34557 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP1A2CYP3A4CYP2C19ADORA3 | |
| SCHEMBL4797073 | 0.96 | CYP1A2 (0.92) | CYP2C9CYP1A2CYP3A4CYP2C19ADORA3 | |
| SCHEMBL4801736 | 0.92 | CYP2C9 (0.85) | CYP2C9CYP1A2CYP3A4CYP2C19ADORA3 | |
| SCHEMBL7350643 | 0.92 | CYP2C9 (0.85) | CYP2C9CYP1A2CYP3A4CYP2C19ADORA3 | |
| SCHEMBL7341251 | 0.92 | CYP2C9 (0.85) | CYP2C9CYP1A2CYP3A4CYP2C19ADORA3 | |
| SCHEMBL7343623 | 0.92 | CYP1A2 (0.85) | CYP2C9CYP1A2CYP3A4CYP2C19ADORA3 | |
| SCHEMBL10924747 | 0.92 | CYP1A2 (0.84) | CYP2C9CYP1A2CYP3A4CYP2C19ADORA3 | |
| SCHEMBL4797084 | 0.92 | CYP1A2 (0.84) | CYP2C9CYP1A2CYP3A4CYP2C19ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22155 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107412-A1 | SARCOSPAN MODULATION AND METHODS OF MEAT AND TISSUE CULTURE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724060-A1 | FORMULATIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HB Biotech, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| WO-1992004011-A1 | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY | ALZA CORPORATION (US) | 1992-03-19 | — | — | WO | claimed |
| WO-1992000729-A1 | DOSAGE FORM FOR ADMINISTERING A DRUG TO EFFECT CIRCADIAN THERAPY | ALZA CORPORATION (US) | 1992-01-23 | — | — | WO | claimed |
| US-5059606-A | COMBINATION OF PYRIMIDINE DERIVATIVES AND CALCIUM ANTAGONISTS TO INDUCE AND STIMULATE HAIR GROWTH AND REDUCE HAIR LOSS | L'OREAL (FR) | 1991-10-22 | — | — | US | claimed |
| WO-1991002497-A1 | TOPICAL NIFEDIPINE FOR CUTANEOUS, OCULAR, MUCOSAL HYPERSENSITIVITY, INFLAMMATORY AND HYPERPROLIFERATIVE CONDITIONS | BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1991-03-07 | — | — | WO | claimed |
| WO-1991002527-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF CUTANEOUS, OCULAR, AND MUCOSAL HYPERSENSITIVITY, INFLAMMATION, AND HYPERPROLIFERATIVE CONDITIONS USING TOPICAL PREPARATIONS OF SEROTONIN ANTAGONISTS | BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1991-03-07 | — | — | WO | claimed |
| WO-1990009376-A1 | A PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE POLYSUBSTITUTED 1,4-DIHYDROPYRIDINES | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1990-08-23 | — | — | WO | claimed |
| US-4950486-A | Dosage form for treating cardiovascular diseases | ALZA CORPORATION (US) | 1990-08-21 | — | — | US | claimed |
| US-4946687-A | Dosage form for treating cardiovascular diseases | ALZA CORPORATION (US) | 1990-08-07 | — | — | US | claimed |
| US-4816263-A | Dosage form for treating cardiovascular diseases comprising isradipine | ALZA CORPORATION (US) | 1989-03-28 | — | — | US | claimed |
| EP-0301133-A2 | Long acting formulation | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |